Trial Profile
A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Zenocutuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver metastases; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus First in man; Therapeutic Use
- Acronyms eNRGy
- Sponsors Merus
- 05 Mar 2024 According to a Merus media release, based on recent productive and collaborative discussions with the U.S. Food & Drug Administration, the company will have sufficient clinical data in the first half of 2024 to support potential Biologics License Application submissions in NRG1+ non-small cell lung cancer and NRG1+ pancreatic cancer.
- 12 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
- 12 Jan 2024 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2026.